In late December, pharmacists were authorized to substitute medications within the aflibercept biosimilar group, for which Eylea is the reference product. This highly anticipated decision brings the total number of biosimilars that pharmacists can substitute to 10. However, government authorities will need to ensure that the cap on discounts does not hinder the rollout of biosimilar substitution, which is a source of additional revenue for pharmacists and savings for payers.